World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF KIDNEY CANCER USING SIMILAR MOLECULE - AXITINIB AMIDE

Dr. Syed Ahmed Hussain*, Maimuna Fatima, Umaima Batool Osmani, Arshiya Tarannum, Faheem Unnisa, Raheem Unnisa Shaik and Nazneen

ABSTRACT

Aim: This study aims to evaluate the cytotoxic effects of Axitinib Amide on kidney cancer cells using multiple in vitro assays. Objective: The primary objective is to assess the dose-dependent inhibition of kidney cancer cell viability by Axitinib Amide and to compare its activity against the control compound, Everolimus. Research: Kidney cancer cells were treated with increasing concentrations (1 μM, 5 μM, and 10 μM) of Axitinib Amide. The assays performed include MTT, CellTiter-Glo Luminescent Cell Viability, Alamar Blue, Sulforhodamine B (SRB), and LDH Cytotoxicity. The results demonstrated a consistent reduction in cell viability across MTT, CellTiter-Glo, Alamar Blue, and SRB assays, indicating a strong dose-dependent cytotoxic effect. However, the LDH Cytotoxicity Assay showed an increase in cell viability at higher concentrations, suggesting potential alternate mechanisms of action or off-target effects. Conclusion: Axitinib Amide exhibited potent dose-dependent cytotoxicity against kidney cancer cells in multiple assays. Although the results were generally consistent, the divergent findings in the LDH Cytotoxicity Assay highlight the need for further research to understand its full pharmacological profile and mechanism of action.

[Full Text Article]   [Download Certificate]